Metformin Versus Vildagliptin for Diabetic Hypertensive Patients
Reducing the Elevated Blood Pressure for Diabetic Hypertensive Patients

About this trial
This is an interventional treatment trial for Reducing the Elevated Blood Pressure for Diabetic Hypertensive Patients focused on measuring diabetes, Metformin, vildagliptin, hypertension, cardiovascular risk
Eligibility Criteria
Inclusion Criteria:
- Patients suffering from moderate HTN and DM, their HbA1c ≥ 7 and age range between 40-60 years, treatment with diet alone, any combination of oral antidiabetic agents and/or insulin before admission
Exclusion Criteria:
- Clinical evidence of ischemic heart disease, chronic obstructive pulmonary disease, presence of diabetic ketoacidosis (DKA), patients admitted to intensive care unit (ICU), subjects expected to undergo surgery during the study period, patients with clinically relevant hepatic disease, impaired renal function (serum creatinine ≥3.0 mg/dL), systemic infections or pregnancy. Also, patients on medications known to interfere with the blood glucose level (either increasing or decreasing) were excluded from the study.
Sites / Locations
- National institute of diabetes and endocrinology
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
No Intervention
No Intervention
Other
Other
Healthy control
diabetic hypertensive recently diagnosed patients
Metformin treated group
Vildagliptin treated group
healthy volunteers not suffering from diabetes or hypertension
recently diagnosed patients suffers from diabetes type 2 and hypertension but didnot receive their proper treatment yet
diabetic hypertensive patients which were treated with captopril for their hypertension and metformin for their diabetes
diabetic hypertensive patients which were treated with captopril for their hypertension and vildagliptin for their diabetes